|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6-12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:ChanSS,
pubmed-author:ColomboNN,
pubmed-author:Filipczyk-CisarzEE,
pubmed-author:HagbergHH,
pubmed-author:KayeS BSB,
pubmed-author:KoneDD,
pubmed-author:LebedinskyCC,
pubmed-author:MonkB JBJ,
pubmed-author:NietoAA,
pubmed-author:ParekhTT,
pubmed-author:ParkY CYC,
pubmed-author:PovedaAA,
pubmed-author:RoyMM,
pubmed-author:SantabárbaraPP,
pubmed-author:TjulandinSS,
pubmed-author:VergoteII
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
49-58
|
|
pubmed:meshHeading |
pubmed-meshheading:20643863-Adult,
pubmed-meshheading:20643863-Aged,
pubmed-meshheading:20643863-Aged, 80 and over,
pubmed-meshheading:20643863-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20643863-Dioxoles,
pubmed-meshheading:20643863-Doxorubicin,
pubmed-meshheading:20643863-Drug Administration Schedule,
pubmed-meshheading:20643863-Female,
pubmed-meshheading:20643863-Humans,
pubmed-meshheading:20643863-Middle Aged,
pubmed-meshheading:20643863-Organoplatinum Compounds,
pubmed-meshheading:20643863-Ovarian Neoplasms,
pubmed-meshheading:20643863-Polyethylene Glycols,
pubmed-meshheading:20643863-Recurrence,
pubmed-meshheading:20643863-Tetrahydroisoquinolines,
pubmed-meshheading:20643863-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
|
|
pubmed:affiliation |
Section of Medicine, Institute of Cancer Research, The Royal Marsden Hospital, Sutton, Surrey, UK. stan.kaye@rmh.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
